Hipercium species in the treatment of depression - a literature overview
DOI:
https://doi.org/10.12775/QS.2025.42.60806Keywords
Hypericum perforatum, St. John’s wort, herbal medicine, depression, phytotherapy, mental health, antidepressant effect, natural remediesAbstract
Hypericum perforatum, commonly known as St. John’s wort, has gained considerable attention as a herbal alternative in the treatment of mild to moderate depression. Given its favorable safety profile, natural origin, and evidence-based efficacy, it may represent a valuable support tool in mental health care, including among physically active individuals. The plant’s therapeutic potential stems from the synergistic action of compounds such as hyperforin and hypericin, which modulate neurotransmitter systems and neuroinflammation. Clinical studies and meta-analyses confirm that H. perforatum demonstrates comparable effectiveness to conventional antidepressants, while showing fewer side effects. Although its interaction with other medications requires caution, the growing interest in phytotherapy highlights its relevance in supporting psychological well-being, especially in stress-prone populations, such as athletes or individuals seeking non-pharmacological interventions.
References
[1]E. A. Apaydin et al., “A systematic review of St. John’s wort for major depressive disorder,” Syst Rev, vol. 5, no. 1, Sep. 2016, doi: 10.1186/s13643-016-0325-2.
[2]L. Dobrek and K. Głowacka, “Depression and Its Phytopharmacotherapy—A Narrative Review,” Mar. 01, 2023, Multidisciplinary Digital Publishing Institute (MDPI). doi: 10.3390/ijms24054772.
[3]T. Li et al., “Hyperibone J exerts antidepressant effects by targeting ADK to inhibit microglial P2X7R/TLR4-mediated neuroinflammation,” J Adv Res, 2024, doi: 10.1016/j.jare.2024.07.015.
[4]L. Dobrek and K. Głowacka, “Depression and Its Phytopharmacotherapy—A Narrative Review,” Mar. 01, 2023, Multidisciplinary Digital Publishing Institute (MDPI). doi: 10.3390/ijms24054772.
[5]N. Zirak, M. Shafiee, G. Soltani, M. Mirzaei, and A. Sahebkar, “Hypericum perforatum in the treatment of psychiatric and neurodegenerative disorders: Current evidence and potential mechanisms of action,” Jun. 01, 2019, Wiley-Liss Inc. doi: 10.1002/jcp.27781.
[6]M. C. Otero et al., “Documentary Analysis of Hypericum perforatum (St. John’s Wort) and Its Effect on Depressive Disorders,” Dec. 01, 2024, Multidisciplinary Digital Publishing Institute (MDPI). doi: 10.3390/ph17121625.
[7]F. Di Pierro, P. Risso, and R. Settembre, “Role in depression of a multi-fractionated versus a conventional Hypericum perforatum extract,” Panminerva Med, vol. 60, no. 4, pp. 156–160, Dec. 2018, doi: 10.23736/S0031-0808.18.03518-8.
[8]J. S. Canenguez Benitez et al., “Advantages and Disadvantages of Using St. John’s Wort as a Treatment for Depression,” Cureus, Sep. 2022, doi: 10.7759/cureus.29468.
[9]M. Kenda, N. Kočevar Glavač, M. Nagy, and M. Sollner Dolenc, “Medicinal Plants Used for Anxiety, Depression, or Stress Treatment: An Update,” Sep. 01, 2022, MDPI. doi: 10.3390/molecules27186021.
[10]N. Galeotti, “Hypericum perforatum (St John’s wort) beyond depression: A therapeutic perspective for pain conditions,” Mar. 22, 2017, Elsevier Ireland Ltd. doi: 10.1016/j.jep.2017.02.016.
[11]P. Rizzo, L. Altschmied, B. M. Ravindran, T. Rutten, and J. C. D’auria, “The biochemical and genetic basis for the biosynthesis of bioactive compounds in hypericum perforatum L., one of the largest medicinal crops in Europe,” Oct. 01, 2020, MDPI AG. doi: 10.3390/genes11101210.
[12]A. Theodorakopoulou, I. Pylarinou, I. A. Anastasiou, and N. Tentolouris, “The Putative Antidiabetic Effect of Hypericum perforatum on Diabetes Mellitus,” Jan. 01, 2025, Multidisciplinary Digital Publishing Institute (MDPI). doi: 10.3390/ijms26010354.
[13]Z. İlhan, M. Zengin, O. K. Bacaksız, E. Demir, İ. H. Ekin, and M. A. Azman, “Hypericum perforatum L. (St. John’s Wort) in broilers diet improve growth performance, intestinal microflora and immunity,” Poult Sci, vol. 103, no. 12, Dec. 2024, doi: 10.1016/j.psj.2024.104419.
[14]J. Barnes, L. A. Anderson, and J. D. Phillipson, “St John’s wort (Hypericum perforatum L.) : a review of its chemistry, pharmacology and clinical properties,” Journal of Pharmacy and Pharmacology JPP, vol. 53, pp. 583–600, 2001.
[15]Z. Ayati, J. Sarris, D. Chang, S. A. Emami, and R. Rahimi, “Herbal medicines and phytochemicals for obsessive–compulsive disorder,” Aug. 01, 2020, John Wiley and Sons Ltd. doi: 10.1002/ptr.6656.
[16]I. s. Moragrega and J. L. Ríos, “Medicinal Plants in the Treatment of Depression: Evidence from Preclinical Studies,” Aug. 01, 2021, Georg Thieme Verlag. doi: 10.1055/a-1338-1011.
[17]G. Di, C. F. Borrelli, A. A. Izzo, and E. Ernst, “Review,” 2001. [Online]. Available: http://tips.trends.com0165
[18]S. Nicolussi, J. Drewe, V. Butterweck, H. E. Meyer Zu Schwabedissen, and H. E. Meyer, “Clinical relevance of St. John’s wort drug interactions revisited,” 2019, doi: 10.1111/bph.v177.6/issuetoc.
[19]S. Z. Nobakht, M. Akaberi, A. H. Mohammadpour, A. T. Moghadam, and S. A. Emami, “Hypericum perforatum: Traditional uses, clinical trials, and drug interactions,” Iran J Basic Med Sci, vol. 26, no. 9, pp. 1045–1058, Sep. 2022, doi: 10.22038/IJBMS.2022.65112.14338.
[20]V. Butterweck, “Mechanism of Action of St John’s Wort in Depression What is Known?,” 2003.
[21]N. Zirak, M. Shafiee, G. Soltani, M. Mirzaei, and A. Sahebkar, “Hypericum perforatum in the treatment of psychiatric and neurodegenerative disorders: Current evidence and potential mechanisms of action,” Jun. 01, 2019, Wiley-Liss Inc. doi: 10.1002/jcp.27781.
[22]Z. Xu, A. M. Rasteh, A. Dong, P. Wang, and H. Liu, “Identification of molecular targets of Hypericumperforatum in blood for major depressive disorder: a machine-learning pharmacological study,” Chinese Medicine (United Kingdom), vol. 19, no. 1, Dec. 2024, doi: 10.1186/s13020-024-01018-5.
[23]R. C. Shelton, “St John’s wort (Hypericum perforatum) in major depression,” Journal of Clinical Psychiatry, vol. 70, no. SUPPL. 5, pp. 23–27, 2009, doi: 10.4088/JCP.8157su1c.05.
[24]R. Rahimi, S. Nikfar, and M. Abdollahi, “Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: A meta-analysis,” Prog Neuropsychopharmacol Biol Psychiatry, vol. 33, no. 1, pp. 118–127, Feb. 2009, doi: 10.1016/j.pnpbp.2008.10.018.
[25]X. Zhao, H. Zhang, Y. Wu, and C. Yu, “The efficacy and safety of St. John’s wort extract in depression therapy compared to SSRIs in adults: A meta-analysis of randomized clinical trials,” Advances in Clinical and Experimental Medicine, vol. 32, no. 2, pp. 151–161, Feb. 2023, doi: 10.17219/acem/152942.
[26]E. A. Apaydin et al., “A systematic review of St. John’s wort for major depressive disorder,” Syst Rev, vol. 5, no. 1, Sep. 2016, doi: 10.1186/s13643-016-0325-2.
[27]D. Scuteri and B. Nephew, “St. John’s Wort usage in treating of perinatal depression.”
[28]W. Schäfer, N. Wentzell, T. Schink, and U. Haug, “Characterization of pregnancies exposed to St. John’s wort and their outcomes: A claims data analysis,” Reproductive Toxicology, vol. 102, pp. 90–97, Jun. 2021, doi: 10.1016/j.reprotox.2021.04.005.
[29]D. Richter et al., “Selective serotonin reuptake inhibitors for the prevention of post-stroke depression: A systematic review and meta-analysis,” J Clin Med, vol. 10, no. 24, Dec. 2021, doi: 10.3390/jcm10245912.
[30]S. M. Nabavi et al., “The water extract of tutsan (Hypericum androsaemum L.) red berries exerts antidepressive-like effects and in vivo antioxidant activity in a mouse model of post-stroke depression,” Biomedicine and Pharmacotherapy, vol. 99, pp. 290–298, Mar. 2018, doi: 10.1016/j.biopha.2018.01.073.
[31]A. Eatemadnia, S. Ansari, P. Abedi, and S. Najar, “The effect of Hypericum perforatum on postmenopausal symptoms and depression: A randomized controlled trial,” Complement Ther Med, vol. 45, pp. 109–113, Aug. 2019, doi: 10.1016/j.ctim.2019.05.028.
[32]X. Ma et al., “Hypericum Perforatum-Derived Exosomes-Like Nanovesicles: A Novel Natural Photosensitizer for Effective Tumor Photodynamic Therapy,” Int J Nanomedicine, vol. 20, pp. 1529–1541, 2025, doi: 10.2147/IJN.S510339.
[33]S. Czigle, M. Nagy, P. Mladěnka, and J. Tóth, “Pharmacokinetic and pharmacodynamic herb-drug interactions—part I. Herbal medicines of the central nervous system,” PeerJ, vol. 11, p. e16149, Nov. 2023, doi: 10.7717/peerj.16149.
[34]N. Mikkelsen, P. Damkier, and S. A. Pedersen, “Serotonin syndrome—A focused review,” Aug. 01, 2023, John Wiley and Sons Inc. doi: 10.1111/bcpt.13912.
[35]C. Talton, “Serotonin Syndrome/Serotonin Toxicity,” Federal Practitioner, no. Vol 37 No 10, Oct. 2020, doi: 10.12788/fp.0042.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Justyna Drożdżał, Oliwia Barańska, Małgorzta Chańko, Adam Krzaczkowski, Emilia Niedzielska, Magadalena Rędaszka, Joanna Szuba, Zofia Szular, Tymon Wojczulis, Katarzyna Ziemek
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 60
Number of citations: 0
